



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Jieyan Shen
✉ shenjy_66@163.com

[†]These authors have contributed equally to
this work

RECEIVED 16 January 2024
ACCEPTED 18 January 2024
PUBLISHED 21 February 2024

CITATION

Wang A, Chen M, Zhuang Q, Guan L, Xie W,
Wang L, Huang W, Cheng Z, Yu S, Zhou H and
Shen J (2024) Corrigendum: Time to clinical
improvement: an appropriate surrogate
endpoint for pulmonary arterial hypertension
medication trials.
Front. Cardiovasc. Med. 11:1371699.
doi: 10.3389/fcvm.2024.1371699

COPYRIGHT

© 2024 Wang, Chen, Zhuang, Guan, Xie,
Wang, Huang, Cheng, Yu, Zhou and Shen. This
is an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

An Wang^{1†}, Mengqi Chen^{1†}, Qi Zhuang¹, Lihua Guan², Weiping Xie³,
Lan Wang⁴, Wei Huang⁵, Zhaozhong Cheng⁶, Shiyong Yu⁷,
Hongmei Zhou⁸ and Jieyan Shen^{1*}

¹Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ²Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China, ³Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ⁴Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China, ⁵Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ⁶Respiratory Department, The Affiliated Hospital of Qingdao University, Qingdao, China, ⁷Department of Cardiology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing, China, ⁸Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China

KEYWORDS

pulmonary arterial hypertension, time to clinical improvement, efficacy, risk stratification, 6-min walk distance

A Corrigendum on

Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials

By Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, Huang W, Cheng Z, Yu S, Zhou H, Shen J. (2023). *Front Cardiovasc Med.* 10:1142721. doi: 10.3389/fcvm.2023.1142721

Incorrect Funding

In the published article, there was an error in the Funding statement.

There was an error in specifying the grant number of National Natural Science Foundation of China (CN) in the Funding section of the paper. The correct grant number is [81970047] and [82270050], but it was mistakenly written as [81800047].

The original text was: This work was supported by the National Natural Science Foundation of China (CN) (81800047) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).

The correct Funding statement appears below.

Funding

This work was supported by the National Natural Science Foundation of China (CN) (81970047, 82270050) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.